Labcorp Holdings Inc

LH remains in a Stage 2 advancing uptrend with an active Lockout Rally underscoring urgency-driven repricing. Price has pulled back into rising 9/21 EMA support and is holding above key moving averages, offering a tactical entry despite extreme overbought conditions. Medium- and long-term biases stay bullish, justifying immediate participation on this shallow pullback.

• ↑Q2 2025 revenue rose 10% to $3.5B; diagnostics up 5% YoY
• ↑Free cash flow of $543M and $211M in Q1 M&A boost growth
• ↓PAMA could cut revenue by about $100M, pressuring pricing